The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...
Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...
3don MSN
As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...
As the company continues to push for GLP-1 market share, it has tapped an internal veteran with recent experience managing research and development finance.
Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...
AMERICAN pharmaceutical company Eli Lilly has invested US$1bn into the expansion of its manufacturing site in Limerick, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback